Ophthalmology News

What risks should we accept in exchange for a miracle?

The FDA has extended its Prescription Drug User Fee Act date for the biologics license application for NT-501, a treatment for macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

Recent research has suggested that GLP-1 agonists used to treat obesity might be associated with a stroke in the optic nerve, but association is not the same as causation.

A paper recently published in JAMA Ophthalmology by Hathaway and colleagues at Harvard suggested a potential association between prescribed semaglutide and an increased risk for nonarteritic anterior ischemic optic neuropathy.

Traumatic iris repair is not uncommon.

As ophthalmologists, we face almost daily pressure to adopt the latest and greatest technologies and techniques. With so much competing information, it can be challenging to know what new innovations are truly worth pursuing.

“Perfect partners don’t exist. Perfect conditions exist for a limited time in which partnerships express themselves best.”

Drugs utilized to treat systemic diseases can do harm to the eye and its neural connections.

A 53-year-old man presented to the comprehensive ophthalmology service at New England Eye Center for a second opinion of a new dark gray spot in his upper right visual field.